Animal Cell, Per Se (e.g., Cell Lines, Etc.); Composition Thereof; Process Of Propagating, Maintaining Or Preserving An Animal Cell Or Composition Thereof; Process Of Isolating Or Separating An Animal Cell Or Composition Thereof; Process Of Preparing A Composition Containing An Animal Cell; Culture Media Therefore Patents (Class 435/325)
  • Patent number: 10982055
    Abstract: The present disclosure provides thermoreversible polymers, hydrogel compositions comprising the thermoreversible polymers, as well as methods of making and using the thermoreversible polymers.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: April 20, 2021
    Assignee: The Regents of the University of California
    Inventors: Christina Marie Fuentes, Barbara L. Ekerdt, David V. Schaffer, Rachel Segalman, Yuguo Lei
  • Patent number: 10980873
    Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 20, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES
    Inventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
  • Patent number: 10980221
    Abstract: Provided herein are methods and compositions related to non-human animals that express exogenous Terminal Deoxynucleotidyltransferase (TdT).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 20, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Chunguang Guo, Natasha Levenkova, Naxin Tu, John McWhirter, Vera Voronina, Faith Harris
  • Patent number: 10966734
    Abstract: A surgical instrument includes a first member defining an axis and having a scraping surface configured to scrape tissue. A second member includes a cutting surface that is rotatable relative to the first member. The second member has a maximum length defined by opposite end surfaces of the second member. The end surfaces are each disposed within the first member. A third member includes an outer surface defining at least a portion of a passageway configured for disposal of the scraped tissue. The third member is fixed with the first member. The cutting surface is rotatable relative to the third member to transfer the scraped tissue along the axis. Systems and methods are disclosed.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 6, 2021
    Inventors: Darren L. Davis, Eric C. Lange
  • Patent number: 10961493
    Abstract: When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 30, 2021
    Assignees: DAIKIN INDUSTRIES, LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Tatsuya Higuchi, Kozue Komazawa, Yoshiko Mohara, Takayuki Dempo, Masuhiro Nishimura
  • Patent number: 10961511
    Abstract: The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: March 30, 2021
    Inventors: Lars Norman Sachs, Ana Gracanin, Jarno Drost
  • Patent number: 10953140
    Abstract: The present invention is directed to a method of producing a tissue graft, comprising at least steps of providing a gel, seeding the gel with cells of at least a first and/or cells of a second type, and culturing of the cells of the first and/or cells of the second type in said gel until the formation of at least one first biostructure in the gel by the cells of the first type and/or the cells of the second type.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 23, 2021
    Assignee: UNIVERSITAT ZURICH
    Inventors: Ernst Reichmann, Daniela Marino, Agnieszka Sylwia Klar
  • Patent number: 10942170
    Abstract: Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: March 9, 2021
    Assignee: Ares Trading S.A.
    Inventors: Lei Tan, Martin Chian, Alice Chen Kim, Peter Lorenzen
  • Patent number: 10941202
    Abstract: The invention concerns pluri- or multipotent stem cells (SCs), e.g. human pluri- or multipotent stem cells (hSCs) engineered to express a multispecific antibody and which further express, on their surface, a human immune cell co-stimulatory ligand or an active fragment thereof.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: March 9, 2021
    Assignee: GEMOAB MONOCLONALS GMBH
    Inventor: Armin Ehninger
  • Patent number: 10927411
    Abstract: Genetic tests, such as whole genome analysis (WGA), have been employed to identify genetically superior embryos. The disclosed methods extend in vitro culture time of embryos while awaiting results of genetic tests being performed on a portion of the same embryos. The disclosed methods also help expand the number of cells in each embryo before implantation in the recipient.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: February 23, 2021
    Assignee: TRANS OVA GENETICS, L.C.
    Inventors: Poothappillai K. Kasinathan, Hong Wei, Mark F. Allan, David C. Faber
  • Patent number: 10927154
    Abstract: The disclosure provides a multi-specific polypeptide with a first moiety specific for a tumor-associated antigen on tumor cell surface and a second moiety specific for an immune checkpoint protein, which multi-specific polypeptide can be useful for biasing a T-cell-mediated response to a tumor micro-environment. For example, the polypeptide may contain: a) a first binding domain, for example, a full-length antibody or an antigen-binding domain of an antibody, specifically recognizing a tumor-associated antigen on tumor cell surface, and b) a second binding domain, such as a lipocalin mutein, capable of stimulating T-cell proliferation e.g., by inhibiting a protein receptor that down-regulates the immune system. The first binding domain may be genetically linked (i.e., peptide bond at its N- or C-terminus) to the second binding domain. The multispecific polypeptide also may contain a third or yet additional specific binding moieties, any of which can specifically bind a distinct immune checkpoint protein.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: February 23, 2021
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer, Rachida Bel Aiba, Gabriele Matschiner, Bradley Lunde
  • Patent number: 10927349
    Abstract: Provided are cytoplasts (enucleated cells), methods for making cytoplasts, compositions comprising cytoplasts, and methods for using cytoplasts.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: February 23, 2021
    Assignee: The Regents of the University of California
    Inventors: Richard Klemke, Huawei Wang
  • Patent number: 10920237
    Abstract: The invention relates to a method for increasing the frequency of meiotic recombination in plants, by inhibiting the RECQ4 or TOP3A protein, especially by mutagenesis or extinction of the RECQ4 or TOP3A gene coding for said protein. The invention can be used especially in the field of plant breeding and genetic mapping.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: February 16, 2021
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
    Inventors: Raphaël Mercier, Mathilde Seguela-Arnaud, Wayne Crismani
  • Patent number: 10913925
    Abstract: The systems and methods disclosed herein are generally related to a cell culture system. More particularly, the systems and methods enable the culturing and interconnecting of a plurality of tissue types in a biomimetic environment. By culturing organ specific tissue types within a biomimetic environment and interconnecting each of the organ systems in a physiologically meaningful way, experiments can be conducted on in vitro cells that substantially mimic the responses of in vivo cell populations. In some implementations, the system is used to monitor how organ systems respond to agents such as toxins or medications. The system enables the precise and controlled delivery of these agents, which, in some implementations, enables the biomimetic dosing of drugs in humans to be mimicked.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 9, 2021
    Assignees: The Charles Stark Draper Laboratory, Inc., The Massachusetts Institute of Technology
    Inventors: Joseph Cuiffi, Jeffrey T. Borenstein, Anilkumar Harapanahalli Achyuta, Mark J. Mescher, Linda Griffith, Samuel Walker Inman
  • Patent number: 10913948
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 9, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • Patent number: 10889792
    Abstract: A method includes introducing a suspension including cells suspended in a cell culture medium through a feed port or a drain port into a cavity of a cell culture vessel, the suspension being in an amount sufficient to cover a gas permeable, liquid impermeable membrane positioned at a bottom of the cell culture vessel, the feed port being disposed through a surface of the cell culture vessel and configured to permit additional cell culture medium into the cavity, and the drain port being disposed through the surface of the cell culture vessel and configured to permit removal of the cells, cell culture medium, and used cell culture medium from the cavity, allowing the cells to settle on the gas permeable, liquid impermeable membrane by gravity, removing the used cell culture medium through the drain port and introducing the additional cell culture medium through the feed port such that a constant volume is maintained in the cell culture vessel until the cells expand to a desired cell density, wherein the removi
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: January 12, 2021
    Assignee: Global Life Sciences Solutions USA LLC
    Inventors: Weston Blaine Griffin, Xiaohua Zhang, Reginald Donovan Smith, Vandana Keskar
  • Patent number: 10883078
    Abstract: A culture device supplying an accurate amount of liquid into a culture bag has a culture bag having ports, a first bag holding portion having supporting surfaces supporting the culture bag, a rotation mechanism rotating the first bag holding portion, a liquid supplying mechanism supplying a liquid through a tube communicating with the ports a weight detector detecting the weight of the culture bag and the first bag holding portion, and a control portion, in which the control portion sets a first reference value according to a first detection information output from the weight detector in a first state and carries out a liquid supplying step of stopping the liquid supplying mechanism under the condition where a second detection information output from the weight detector when a liquid is supplied to the culturing bag reaches a first target value obtained by adding the weight of the liquid to be supplied to the first reference value.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: January 5, 2021
    Inventors: Norihisa Sasayama, Masakatsu Takeuchi, Atsushi Taguchi
  • Patent number: 10865242
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. In some alternatives, the ligand binding domains binds to CD171.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: December 15, 2020
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Patent number: 10858656
    Abstract: Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against KRAS. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against KRAS.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 8, 2020
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventor: Hanhua Huang
  • Patent number: 10851346
    Abstract: The present invention relates to a mesenchymal stem cell having immunomodulatory activity and a preparation method therefor and, more specifically, to: a rapamycin-treated mesenchymal stem cell having immunomodulatory activity, which expresses any one or more cell surface factors selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR7, CCR9 and CXCR4; a cell therapy composition comprising the mesenchymal stem cell, for preventing or treating immune disorders; and a preparation method for the mesenchymal stem cell having immunomodulatory activity. The rapamycin-treated mesenchymal stem cell having immunomodulatory activity, according to the present invention, has increased expression of IDO, TGF-? and IL-10 which are factors having immunomodulatory activity, has decreased expression of Phospho-mTOR, Rictor and Ractor which are signal transduction factors of mTOR, and has increased expression, in the cell, of autophagic inducer Beclin1, ATG5, ATG7, LC3I or LCII.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: December 1, 2020
    Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY—ACADEMIC COOPERATION FOUNDATION
    Inventors: Chul Woo Yang, Mi-La Cho, Sung-Hwan Park, Eun Kyung Kim, Byung Ha Chung, Kyoung-Woon Kim, Seon-Yeong Lee, Sung-Hee Lee, Eun Ji Yang, Jeong-hee Jeong, Min Jung Park, Seok-Jung Kim, Eun-Jung Lee, Su-Jin Moon
  • Patent number: 10842735
    Abstract: Provided is a hair growth-promoting composition comprising: 100 parts by weight of a stem cell culture solution obtained from a culture medium of mesenchymal stem cells which have been subcultured two or more times; 0.001 to 0.1 parts by weight of zinc; 5 to 50 parts by weight of a panthenol based compound; and 0.0001 to 0.1 parts by weight of a water-soluble vitamin, wherein it is sprayed or applied on the scalp to promote hair growth. Said hair growth-promoting composition may have an excellent effect and improve economical efficiency in treating alopecia due to a simple delivery method of the composition.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 24, 2020
    Inventor: Dong Hyun Ahn
  • Patent number: 10844364
    Abstract: A system for accelerating the migration of cells by applying a time-varying magnetic field to induce eddy currents that promote electrotaxis (galvanotaxis) of cells. The system of the present invention accelerates the healing of wounds by electrotaxis of cells.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 24, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Vish Subramaniam, Joseph West, Emily Alkandry, Sashwati Roy, Chandan Sen, Piya Ghatak
  • Patent number: 10835609
    Abstract: In some aspects, methacrylate co-polymers crosslinked with an enzymatically cleavable peptide linker are provided and may be used for the oral delivery of a therapeutic. The peptide linker may be cleavable by an enzyme in the small intestine and may allow for the delivery of a therapeutic protein or nucleic acid to the small intestine. Also provided are methods of using the polymers for the treatment of a disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 17, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jennifer M. Knipe, Laura E. Strong, Nicholas A. Peppas
  • Patent number: 10828346
    Abstract: There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: November 10, 2020
    Assignee: Ottawa Hospital Research Institute
    Inventors: Michael A. Rudnicki, Fabien Le Grand
  • Patent number: 10822595
    Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 3, 2020
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10814015
    Abstract: The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human FKBP51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline transactivator (tTA) operably linked to a promoter; wherein the tTA is expressed upon activation of the promoter and binds the tetracycline response element, thereby causing expression of FKBP51. The invention also pertains to methods for screening for agents for the prevention and/or treatment of psychiatric disorders, such as depression.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: October 27, 2020
    Assignee: University of South Florida
    Inventors: Chad Dickey, Bo Zhang, Laura Jenelle Blair
  • Patent number: 10808279
    Abstract: The invention generally relates to detecting target molecules.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: October 20, 2020
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Darren Roy Link, Benjamin J. Miller
  • Patent number: 10801002
    Abstract: A method of forming a tissue engineered construct, a bioreactor for forming a tissue engineered construct, and a tissue engineered construct itself are disclosed. The disclosed method includes seeding a scaffold with cells to form a tissue construct; locating the tissue construct in a space defined by a tissue construct support element; locating the tissue construct support element within a bioreactor; and operating a load applicator of the bioreactor to apply a cyclical compressive mechanical load to the tissue construct, to stimulate the deposition of tissue matrix in the tissue construct; in which the tissue construct, the tissue construct support element and the load applicator are arranged so that the load applicator can at least initially contact both the tissue construct and the tissue construct support element, so that at least part of a total load generated by the load applicator is borne by the tissue construct support element.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: October 13, 2020
    Assignees: UNIVERSITY OF LEEDS, XIROS LIMITED
    Inventors: Scott Finlay, Bahaa Botros Seedhom
  • Patent number: 10779520
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: September 22, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • Patent number: 10781421
    Abstract: The present invention pertains to a method for the generation of neurotoxin-sensitive, neuronal differentiated cells comprising the steps of: a) cultivating tumor cells which are able to differentiate into neuronal cells in a culture medium under conditions and for a time which primes said tumor cells for neuronal differentiation; and b) cultivating the tumor cells primed for neuronal differentiation of a) in a differentiation medium having an osmolality of 100 to 270 mOsm/kg, and comprising (i) B27 supplement and/or (ii) N2 supplement, for at least 3 days, thereby obtaining neurotoxin-sensitive, neuronal differentiated cells. The invention further relates to neurotoxin-sensitive, neuronal differentiated cells obtainable by the method of the invention.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: September 22, 2020
    Assignee: MERE PHARMA GmbH & CO. KGaA
    Inventors: Karl-Heinz Eisele, Kai Harting
  • Patent number: 10775364
    Abstract: A method of inducing ischemia includes: providing a cell culture device having a first cell culture in an internal chamber and a second cell culture in at least one fluid channel and a perfusion modulating system that causes changes in oxygen flow in the internal chamber and/or at least one fluid channel; flowing liquid media having oxygen through the internal chamber and at least one fluid channel of the cell culture device; modulating oxygen perfusion in the internal chamber with the perfusion modulating system by varying and selectively blocking the flow rate of at least one of the liquid media or oxygen through the internal chamber to induce varying levels of ischemia; and assaying for ischemia in the first cell culture.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 15, 2020
    Assignee: CFD Research Corporation
    Inventors: Balabhaskar Prabhakarpandian, Kapil Pant
  • Patent number: 10767165
    Abstract: The present invention is in the field of stem cells. Particularly, the present invention relates to a reprogramming method for producing induced pluripotent stem cells (iPSC) by transducing somatic differentiated cells with a viral vector expressing ?133p53? isoform, ?133p53? isoform or both ?133p53? and ?133p53? isoforms; to induced pluripotent stem cells as produced by this method; to uses thereof in cell therapy and as an in vitro model for studying various diseases; and to a method for detecting iPSC.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: September 8, 2020
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventor: Pierre Roux
  • Patent number: 10760057
    Abstract: Methods of using a small molecule MYH11 agonist to inhibit intimal hyperplasia and to maintain a contractile phenotype in vitro and in vivo are described. Also described herein are methods for generating human contractile smooth muscle cells from human pluripotent stem cells under defined conditions in the presence of the small molecule MYH11 agonist.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: September 1, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Jue Zhang
  • Patent number: 10752896
    Abstract: The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the NRARP gene. The invention also relates to the use of said si RNAs molecules in the treatment and/or prevention of a disease or disorder related to neovascularization characterised by increased expression and/or activity of NRARP gene, said eye condition is selected from the group comprising age-related macular degeneration (AMD), ischemic retinopathy, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), diabetic retina ischemia (DRI), diabetic retinal edema (DRE) and retinopathy of prematurity (ROP) and combinations thereof.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: August 25, 2020
    Assignee: SYLENTIS SAU
    Inventors: Ana Isabel Jimenez, Covadonga Pañeda, Tamara Martinez
  • Patent number: 10751715
    Abstract: Functional assays using reporter cell assays are described which probe the activity of at least one cell of interest. The ability to probe at least one cell is provided by using the microfluidic methods, devices and kits described herein. Assays combining both reporter cell signaling as well as binding assay signaling for at least one cell is also described herein.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 25, 2020
    Assignee: Berkeley Lights, Inc.
    Inventors: Xiao Guan, Mark P. White, Jason M. McEwen, Gang F. Wang, Kevin T. Chapman, Xiaohua Wang, Christine E. Sun
  • Patent number: 10745756
    Abstract: Described herein are compounds useful for the treatment and investigation of diseases, methods for the prediction of in vivo toxicity of compounds useful for the treatment and investigation of diseases, and methods of discovering and identifying compounds useful for the treatment and investigation of diseases that have reduced in vivo toxicity.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: August 18, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Sebastien Burel
  • Patent number: 10744207
    Abstract: The disclosure provides complexes comprising targeting units, methods for their production, and methods for their use. In some embodiments, complexes comprise therapeutic agents complexed with targeting units. In some embodiments, complexes comprise cells complexed with targeting units. In view of the foregoing, there is a need for improved modalities for targeting of therapeutics, in the area of immunotherapy and others. The present disclosure addresses these needs, and provides additional advantages as well.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: August 18, 2020
    Assignee: ACEPODIA, INC.
    Inventors: Amy A. Twite, Ching-Wen Hsiao, Sonny Hsiao, Cheng Liu, Hong Liu
  • Patent number: 10724028
    Abstract: The invention provides a ligand-bonded fiber in which a ligand having affinity for a cell membrane receptor is immobilized on a fiber precursor, and a cell culture substrate capable of repeating ex vivo amplification of a cell expressing a cell membrane receptor by using the ligand-bonded fiber.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 28, 2020
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Makiko Umezaki, Takahiro Kishioka, Taito Nishino, Ayako Aihara, Shunsuke Iwamoto, Daisuke Sakuma
  • Patent number: 10703800
    Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: July 7, 2020
    Assignee: LA JOLLA BIOLOGICS, INC.
    Inventors: Christopher T. Leber, Michael W.Y. Shen, Yiwen Tao, Hugh Eugene Murray, IV
  • Patent number: 10696727
    Abstract: The invention provides a method of modulating electrophysiological activity of an excitable cell. The method involves causing exogenous expression of a glycine receptor (GlyR) protein in an excitable cell of a subject. Thereafter, the excitable cell is exposed to an allosteric modulator of the GlyR protein. Modulation of the exogenous GlyR protein (an ion channel) in response to the allosteric modulator modulates the electrophy-stological activity of the excitable cell. The method can be used to control pain in a subject. The invention further provides a replication-defective HSV vector comprising an expression cassette encoding a GlyR protein, stocks and pharmaceutical compositions containing such vectors, and a transgenic animal.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: June 30, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Michael Cascio, Joseph C. Glorioso, III, James R. Goss, David Krisky
  • Patent number: 10696949
    Abstract: The present disclosure provides compositions, systems, and tools for modeling the canine liver and methods of using the same. The disclosure provides micropatterned hepatocyte co-cultures where individual cell populations remain functionally stable during long-term culture.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: June 30, 2020
    Assignee: Ascendance Biotechnology, Inc.
    Inventors: John K. McGeehan, Stacy Krzyzewski, Michael McVay
  • Patent number: 10662411
    Abstract: Cultivating a pluripotent stem cell in a medium comprising at least one member selected from the group consisting of ethanolamine, an ethanolamine analog, and a pharmaceutically acceptable salt thereof, and which is substantially free of ?-mercaptoethanol or contains ?-mercaptoethanol at a concentration of not more than 9 ?M, and the like, is effective for the proliferation of a pluripotent stem cell while maintaining an undifferentiated state.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: May 26, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Sho Senda, Tomomi Yoshida, Satoru Okamoto, Yoko Kuriyama, Manabu Kitazawa, Ikue Harata, Nao Sugimoto
  • Patent number: 10633655
    Abstract: The present invention features compositions and methods relating to tRNA-derived small RNAs (tsRNAs). Provided herein are oligonucleotide compositions that are complementary to tsRNAs, in particular leuCAGtsRNA, and methods of using the oligonucleotides for the regulation of respective tsRNA. Further provided are methods of inducing apoptosis through the inhibition of leuCAGtsRNA.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Hak Kyun Kim, Shengchun Wang
  • Patent number: 10627403
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • Patent number: 10626366
    Abstract: Stem cells such as embryonic stem cells (ES cells), including human ES cells, are cultured in a medium comprising a ROCK inhibitor, and a stem cell culture medium, optionally serum free, comprises a ROCK inhibitor.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 21, 2020
    Assignee: RIKEN
    Inventors: Yoshiki Sasai, Kiichi Watanabe
  • Patent number: 10611994
    Abstract: A device for monitoring a cell culture includes one or more electrochemical sensors configured to be positioned adjacent to or embedded within a medium of a cell culture. The one or more electrochemical sensors are configured to generate signals in accordance with the cell culture. A data storage device is configured to receive and store the signals from the one or more electrochemical sensors. A computation device is configured to analyze the signals from the one or more electrochemical sensors to determine cell activity over time using sensitivity information.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: April 7, 2020
    Assignee: International Business Machines Corporation
    Inventors: Amos Cahan, Guy M. Cohen, Theodore G. van Kessel, Sufi Zafar
  • Patent number: 10612002
    Abstract: Provided herein are methods that enable the polarization of hPSC mesoderm such that closely related yet distinct cardiovascular populations can be generated efficiently without the need of post-facto enrichment.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 7, 2020
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Charles E. Murry, Lil Pabon, Nathan Palpant
  • Patent number: 10610980
    Abstract: A self-heating solder flux material includes a solder flux material and a multi-compartment microcapsule. The solder flux material includes a solvent carrier, and the multi-compartment microcapsule includes a first compartment, a second compartment, and an isolating structure. The first compartment contains a first reactant, and the second compartment contains a second reactant. The isolating structure separates the first compartment from the second compartment. The isolating structure is adapted to rupture in response to a stimulus.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: April 7, 2020
    Assignee: International Business Machines Corporation
    Inventors: Eric J. Campbell, Sarah K. Czaplewski-Campbell, Joseph Kuczynski, Timothy J. Tofil
  • Patent number: 10612004
    Abstract: An in vitro skin equivalent includes at least one epidermis equivalent and at least one dermis equivalent, and further includes melanocytes constitutively producing melanin and fibroblasts.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: April 7, 2020
    Assignee: L'OREAL
    Inventors: Christine Duval, Françoise Bernerd
  • Patent number: 10611998
    Abstract: This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of differentiation factors and mitogens can be used to produce cell populations bearing markers of oligodendrocyte precursor cells. Upon further differentiation form complex processes characteristic of mature oligodendrocytes. The cells are capable of forming myelin sheaths, and can be used therapeutically improve function of the central nervous system.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: April 7, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Hans S. Keirstead, Gabriel I. Nistor